Prostate cancer patients pick their poison: cabazitaxel or docetaxel?
NCT ID NCT02044354
First seen Apr 02, 2026 · Last updated May 25, 2026 · Updated 10 times
Summary
This study asked men with advanced prostate cancer which of two standard chemotherapies they preferred based on side effects. 195 patients tried both drugs in sequence and then stated their preference. The goal was to understand which treatment is better tolerated, helping doctors choose the best option for future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.